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PathogenesisFabry disease is an X-linked lysosomal storage disorder due to deﬁciency of alpha-Galactosidase A, causing
accumulation of globotriaosylceramide and elevated plasma globotriaosylsphingosine (lysoGb3). The
diagnostic value and clinical relevance of plasma lysoGb3 concentration was investigated. All male and
adult female patients with classical Fabry disease could be discerned by an elevated plasma lysoGb3. In
young pre-symptomatic Fabry heterozygotes, lysoGb3 levels can be normal. Individuals carrying the R112H
and P60L mutations, without classical Fabry symptoms, showed no elevated plasma lysoGb3. Multiple
regression analysis showed that there is no correlation of plasma lysoGb3 concentration with total disease
severity score in Fabry males. However, plasma lysoGb3 concentration did correlate with white matter
lesions (odds ratio: 6.1 per 100 nM lysoGb3 increase (95% CI: 1.4–25.9, p=0.015). In females, plasma
lysoGb3 concentration correlated with overall disease severity. Furthermore, plasma lysoGb3 level was
related to left ventricular mass (19.5±5.5 g increase per 10 nM lysoGb3 increase; p=0.001). In addition, it
was assessed whether lifetime exposure to lysoGb3 correlates with disease manifestations. Male Fabry
patients with a high lysoGb3 exposure (N10,000 U), were moderately or severely affected, only one mildly.
Female patients with a low exposure (b1000 U) were asymptomatic or mildly affected. A large proportion of
the females with an exposure N1000 U showed disease complications. Plasma lysoGb3 is useful for the
diagnosis of Fabry disease. LysoGb3 is an independent risk factor for development of cerebrovascular white
matter lesions in male patients and left ventricular hypertrophy in females. Disease severity correlates with
exposure to plasma lysoGb3.).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Fabry disease (OMIM 301500) is caused by deﬁcient activity of the
lysosomal enzyme α-Galactosidase A (E.C. 3.2.1.22) [1]. The deﬁcien-
cy leads to lysosomal accumulation of glycosphingolipids with a
terminal α-galactosyl moiety, in particular globotriaosylceramide
(Gb3), also known as ceramide trihexoside (CTH) [2]. Primarily
affected cells are smooth muscle and endothelial cells, contributing to
the predominance of vascular complications in Fabry disease [3,4].
Although its inheritance is X-linked, both males and females can be
affected by Fabry disease [5–10]. Male patients typically present with
acroparesthesias as well as angiokeratoma and hypo- or anhydrosis
already at a young age. In the third and fourth decade of life, renal,
cardiac, cerebral complications, and hearing loss may develop [4,5].Atypical manifestations have been described for male patients with
high residual enzyme activity. In such individuals the disease may be
limited to one organ only, such as the heart, or may show a milder
course [4–7]. Intriguingly, despite signiﬁcant amounts of residual α-
Galactosidase A activity, female carriers display a vast spectrum of
disease severity, ranging from total absence of clinical disease to
severe organ damage [8–12]. The observed residual enzyme activity in
plasma or blood cells from female carriers varies considerably due to
random X-inactivation, ranging from normal to nearly completely
absent, and is a poor predictor of the clinical course [13]. Also in other
aspects, the relationships between residual enzyme activity, Gb3
accumulation and disease manifestations in Fabry patients are still
puzzling. For example, it has been documented that in male
hemizygotes prominent storage of Gb3 already occurs in utero whilst
clear clinical symptoms develop much later in life [14,15]. Further-
more, it has become apparent that no strict correlation exists between
clinical manifestation of Fabry disease and plasma Gb3 levels
[12,15,17]. In hemizygotes with classical manifestations of Fabry
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young age prior to prominent clinical symptoms, whereas in
heterozygotes, even symptomatic females, Gb3 levels are generally
within the normal range. Based on these ﬁndings, monitoring of the
clinical course in Fabry patients by analysis of their plasma Gb3 is
presently considered to be of little value [12,16,17]. In urine of
symptomatic Fabry patients, both heterozygotes and hemizygotes,
Gb3 levels are generally abnormally high [18,19]. However, again no
correlation of this parameter with disease manifestation has been
observed [12,16,17].
The enigmatic relationships between residual α-Galactosidase A
capacity, Gb3 levels and disease manifestations has prompted us to
consider an additional factor in the pathogenesis of Fabry disease. In
analogy to Krabbe disease, the occurrence of a deacylated storage lipid
was hypothesized. Indeed, globotriaosylsphingosine (lysoGb3) was
found to be dramatically elevated in plasma of all male patients with
classical Fabry disease [20]. Plasma lysoGb3 was also increased in
plasma of symptomatic female patients, although to a lesser extent in
male patients. Comparable ﬁndings were made in Fabry mice lacking
α-Galactosidase A activity [20].
In our initial investigation, a relatively small number of Fabry
patients was studied, in particular few females [20]. In the follow-up
investigation presented here, the entire cohort of Dutch patients with
classic manifestation of Fabry disease was analyzed with respect to
plasma lysoGb3 content. The aim of this study was two-fold. Firstly,
the value of plasma lysoGb3 in conﬁrming the diagnosis of Fabry
disease was determined. This is relevant for individuals carrying an
abnormality in the α-Galactosidase A gene with unknown conse-
quence, or pre-symptomatic female carriers for which demonstration
of true Fabry disease is problematic with present laboratory methods
(e.g. those with normal plasma or urinary Gb3). The second aim of the
investigation was to determine the relationship between plasma
lysoGb3 and clinical manifestations of Fabry disease. Our earlier
observation that lysoGb3 is capable of promoting proliferation of
smooth muscle cells in vitro [20] suggested that lysoGb3 could
contribute to the noted intima media thickening and vascular
pathology, and thus may constitute a risk for disease manifestations
[5,21–23]. The results of our investigation are reported here.
2. Methods
2.1. Patients
All 92 Fabry patients, including 69 adult and 23 paediatric patients
from 28 families, with classical Fabry disease seen at the outpatient
clinic of the Academic Medical Center from 1999 to 2008 were
included in the study. Classical Fabry disease was deﬁned as a
mutation in the α-Galactosidase A gene and the occurrence of typical
manifestations of the disease, such as acroparesthesias, angioker-
atoma, hypo- or anhydrosis in at least one male family member.
Patients with the R112H and P60L mutation did not meet the criteria
of classical Fabry disease and were analyzed separately. Healthy
controls, comparable for age were recruited for analysis of plasma
lysoGb3. None of the patients received enzyme therapy at the time of
plasma lipid analysis. The diagnosis was conﬁrmed by demonstration
of deﬁcient leukocyte α-Galactosidase A activity and genotyping [24].
All patients gave informed consent. For all patients, a full medical
history was obtained as well as a routine physical examination,
including height, weight and blood pressure measurements. Body
mass index was determined and hypertension was diagnosed in case
of a systolic BP≥140 mm Hg and/ or a diastolic BP≥90 mm Hg in
three consecutive measurements performed on the same arm.
Dyslipidemia was diagnosed according to the Dutch guidelines for
dyslipidemia and cardiovascular risk management. Smoking status
was scored as current, smoking in the past, or never smoking. Renal
function (eGFR) was estimated using the abbreviated MDRD equationin adults and the Schwartz formula in children [25,26]. Glomerular
ﬁltration rate (GFR) measured by simultaneous infusion of iothala-
mate and hippuran (mGFR) was performed in adults and in most
children (n=50) and Cr51 EDTA in 2 adult patients. Renal failure was
deﬁned as an mGFRb60 ml/min. Microalbuminuria was deﬁned as
albumin exceeding 30 mg in a 24-h urine portion in two consecutive
portions taken a least 1 week apart. Proteinuria was diagnosed when
total protein count was more than 300 mg in these samples. A
standard brain magnetic resonance imaging (MRI) evaluation for
presence of white matter lesions and (lacunar) infarctions was
available from 83 patients. An electrocardiogram (ECG) and cardiac
ultrasound investigation was available from 87 and 76 patients,
respectively. Left ventricular hypertrophy (LVH) was deﬁned as a left
ventricular mass (LVmass) of N259 g in males and N166 g in females
[27]. Hearing tests were performed by using conventional audiometry
andwere available from 79 patients. Hearing loss was deﬁned as a PTA
(the average hearing loss in dB at 0.5, 1.0 and 2.0 kHz)N25 dB of the
most affected ear [28]. The presence of acroparesthesia was obtained
by medical history of pain in hands and feet. The presence of
angiokeratoma was scored when this was conﬁrmed by physical
examination of the skin by a medical professional specialized in Fabry
disease. Overall severity of disease was assessed by the MSSI scoring
system, a composite score of clinical symptoms [29].2.2. Plasma Gb3 and lysoGb3 measurements
Quantitation of Gb3 in plasma samples was performed as
described previously [30]. Quantitative measurements of plasma
lysoGb3 were performed as described with minor modiﬁcations [20].
In brief, 100 μl of plasma was extracted with 900 μl of chloroform/
methanol 1/2 (vol/vol). The extract was centrifuged for 10 min. at
14,000g and the pellet was discarded. To the supernatant, 300 μl
chloroform and 450 μl MQ-H2Owas added, mixed, and centrifuged for
2 min at 14,000g to separate the phases. The upper phase was
collected, and the lower chloroform phase was re-extracted with
1.2 ml of methanol/ MQ-H2O 1/1 (vol/vol) to quantitatively extract
lysoGb3. The combined upper phases were dried under nitrogen ﬂow,
taken up in 1 ml MQ-H2O, and extracted twice with 1 ml of water-
saturated 1-butanol. LysoGb3 was recovered from the butanol phase
with an overall recovery of N90%. The butanol phase was dried,
dissolved in 120 μl of freshly prepared 0.1 M NaOH in methanol and
incubated at 37 °C for 1 h. Of this solution, 50 μl was derivatized with
25 μl of o-phtaldialdehyde (OPA) reagent (5 mg of OPA, 0.1 ml of
ethanol, 5 μl of 2-mercaptoethanol, and 10 ml of 3% boric acid, pH 9.0).
The OPA-derivatized lysoGb3 was separated by HPLC and identiﬁed
by ﬂuorescence detection as described previously [30]. All plasma
samples were extracted in duplicate. Quantiﬁcation was performed by
addition of lysoGb3 (Sigma-Aldrich) to normal plasma at concentra-
tions ranging from 0 to 1 mM. The limit of detection of plasma
lysoGb3 was 3 nM. Quantiﬁcation of lysoGb3 was based on a
commercially available standard (Sigma-Aldrich) as described earlier
[20]. We plan to synthesize a large batch of lysoGb3 ourselves and use
this standard in the future, given the observation that commercial
lysoGb3 batches show a contamination with N-acetylated lysoGb3.2.3. Electronmicroscopy
After ﬁxation, the material was post ﬁxed in 1% osmiumtetroxide,
block-staining with 1% uranyl acetate, one-step dehydration in
dimethoxypropane and embedding in epoxyresin LX-112. LM sections
were stained with toluidine blue. EM sections were stained with
tannic acid, uranyl acetate and lead citrate and examined in an Philips
CM10 (FEI).
Photographs were taken with a Morada digital camera, (S.I.S.).
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Statistical analyses were performed using SPSS 17.0 (IBM,
Chicago). Results are expressed as median (range). Differences
between groups were assessed by the Mann–Whitney U-test.
Correlations between variables were described by Spearman's rank
correlation coefﬁcients. Multiple regression logistic and linear
regression was used to determine the association between lysoGb3
and disease parameters adjusted for age as a continuous variable,
gender, smoking status, body-mass index and the presence or absence
of a history of hypertension, and the presence of other cardiovascular
disease including diabetes, hemochromatosis and dyslipidemia [31].
Linear regression was applied to quantify the association between
continuous outcome variables and lysoGb3, while logistic regression
was used for binary outcome variables. In the former case, B values
represent the slope of the linear regression line (y=a+B x) while
keeping all other variables constant and reﬂects the change of the
outcome variable when lysoGb3 changes 1 unit (i.e. 10 nM or
100 nM). With logistic regression the odds ratio was determined
which reﬂects the change of the odds of the binary outcome when
lysoGb3 changes 1 unit while keeping all other variables constant.3. Results
3.1. Diagnostic value of plasma lysoGb3
The average age of the male (n=37) and female Fabry patients
(n=55) did not differ signiﬁcantly, themedian being 33 and 35 years,Fig. 1. Diagnostic value of lysoGb3 in Fabry disease. Plasma Gb3 and lysoGb3
concentrations in males (A) and females (B). Males: Gb3: controls n=10, patients
n=36; lysoGb3: controls n=9, patients n=37). Females: Gb3: controls n=13,
patients n=54; lysoGb3: controls n=9, patients n=55).respectively. As has been previously described, lysoGb3 values were
around 15 times higher in males as compared to females [20], ranging
from 51 to 489 (median 286) in males to 0–99 (median 18) in females
(Fig. 1). Also, the disease severity was signiﬁcantly higher in the male
Fabry patients than in female patients, reﬂected in an average higher
MSSI score of 21 and 7, respectively (Table 1).
To determine the usefulness of plasma lysoGb3 measurement for
conﬁrmation of the diagnosis of Fabry disease, the concentrations
of Gb3 and lysoGb3 were determined in plasma specimens of the 92
subjects as well as healthy controls (Fig. 1). In male Fabry patients, a
striking increase in plasma Gb3 concentration was observed. Almost
all of the male Fabry patients could also be recognized by their
abnormally high plasma Gb3 concentration, although in some cases
the Gb3 levels were close to the upper normal range (Fig. 1A). In the
case of female Fabry patients, plasma Gb3 concentration did not allow
a clear discrimination from normal subjects: only few individuals
showed values slightly above the upper normal range (Fig. 1A). In
sharp contrast to the ﬁndings with plasma Gb3, almost all female
Fabry patients showed plasma lysoGb3 concentrations clearly
exceeding normal levels. Only in two heterozygotes aged 5 years
and 7 years respectively, lysoGb3 was within the normal range. The
latter individual showed a plasma lysoGb3 of 5.3 nM at the age of
11 years, slightly above the upper normal range. These ﬁndings
indicate that demonstration of high plasma lysoGb3, (N 3 nM), may be
used for conﬁrming the diagnosis of Fabry disease. A (near) normal
level in very young female individuals however, does however not
exclude the status of a carrier of Fabry disease.
3.2. Age, overall disease severity and plasma lysoGb3 in male and female
Fabry patients
The effect of age on lysoGb3 levels is depicted in Fig. 2. In case of
male Fabry patients, no signiﬁcant correlation was found between
lysoGb3 levels and the age of the investigated individuals. This is
consistent with a previous observation of a high lysoGb3 level in cord
blood of an affectedmale [20]. In female Fabry patients, lysoGb3 levels
showed a trend to be higher in older individuals (ρ=0.25; p=0.06).
Similar ﬁndings were made when plasma lysoGb3 levels were related
to MSSI scores of Fabry patients reﬂecting overall disease severity
(Fig. 3). Male Fabry patients did not show a correlation between
lysoGb3 level andMSSI score (ρ=0.08; p=0.63). In contrast, in female
Fabry patients there was a signiﬁcant, albeit not strict, correlation
between plasma lysoGb3 and MSSI score (ρ=0.53; pb0.0001).
3.3. Plasma lysoGb3 and clinical manifestations
Given the impact of age and gender on disease severity in Fabry
patients, multiple regression analysis was performed to assess
whether plasma lysoGb3 is an independent contributor to disease
manifestations. For this purpose, male and female patients were
analyzed separately. Multiple regression logistic and linear regression
was used to determine the association between lysoGb3 and disease
parameters adjusted for age as a continuous variable, and generalTable 1
Baseline characteristics: lysoGb3 and MSSI score.
Males Females Males vs. females
(p-value)
Number of patients, N 37 55
Age in years Median
(range)
33 (3.6–64) 35 (2.0–71) 0.9
MSSI Median (range) 21 (5–59) 7 (0–32) b0.0001
LysoGb3 (nM) Median (range) 286 (51–489) 18 (0–99) b0.0001
Fig. 2. Relation of plasma lysoGb3 levels and age. Plasma lysoGb3 levels related to age
for 37 male (A) and 55 female patients (B) with Fabry disease. Fig. 3. Relation of plasma lysoGb3 with clinical severity of Fabry disease. Plasma
lysoGb3 levels in 37 male (A) and 55 female patients (B) related to overall disease
severity (Mainz Severity Score Index (MSSI)).
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related to an increase in lysoGb3 of 100 nM; for Fabry femaleswe used
a smaller increment of 10 nM since the range of lipid abnormality in
females is much lower (see Fig. 1). Table 2 shows that based upon
linear regression analysis plasma lysoGb3 is not associated with the
MSSI score in males (1.3 ± 1.0 increase of MSSI score per 100 nM
increase of lysoGb3 (p=0.23)). In contrast, for female Fabry patients a
signiﬁcant association was noted between plasma lysoGb3 and MSSI
score (1.6±0.4 increase of MSSI per 10 nM increase of plasma
lysoGb3 (pb0.001)).
Next, speciﬁc disease manifestations were analysed. When
adjusted for age, plasma lysoGb3 concentration does not appear to
correlate with LVmass in males (p=0.53). However, a signiﬁcant
inﬂuence was noted for the effect on LVmass in female Fabry patients
(24.8±5.6 g increase per 10 nM increase of lysoGb3 (pb0.0001) and
19.5±5.5 (p=0.001) after adjustment for hypertension) (Table 2).
There was no apparent correlation of plasma lysoGb3 concentration
with hearing loss, renal failure (both mGFR and eGFR), microalbumi-
nuria, proteinuria, or presence of angiokeratoma (Table 2).
The association of plasma lysoGb3 with the development of white
matter lesions and cerebrovascular accidents formed a clear excep-
tion. Plasma lysoGb3 concentration contributes independently to the
development of these lesions in the brain in male Fabry patients. The
odds ratio was 6.1 (95% CI: 1.4–25.9) per 100 nM lysoGb3 increase
(p=0.015). In females the odds ratio was 1.2 (95% CI: 0.9–1.9) per
10 nM lysoGb3 increase, which was not signiﬁcant (p=0.18). Fig. 4
illustrates the occurrence of cerebrovascular white matter lesions for
male Fabry patients. Most male patients around 35 years develop
brain lesions [32]. The ones without such white matter abnormalities
all have comparatively low plasma lysoGb3 levels (see Fig. 4). In
females (not shown), the patient with the highest plasma lysoGb3
had a white matter lesion already at the age of 13.3.4. Exposure to plasma lysoGb3 and clinical manifestations
Next we examined whether the lifetime exposure to lysoGb3
contributes to the likelihood of presentation of symptoms. Maximum
lifetime exposure was estimated by calculating the product of plasma
lysoGb3 concentration and the age of an individual. This is very likely an
overestimation in the case of female Fabry patients. The calculated
cumulative lysoGb3 exposure of individual Fabry patients was com-
pared to the disease severity (see Table 3). For this purpose, patients
were stratiﬁed as asymptomatic or mildly affected (MSSI 0–19),
moderately affected (MSSI 20–39), or severely affected (MSSI N40)
[29]. Four ranges of exposure valueswere distinguished: 0–1000, 1000–
5000, 5000–10,000 and N10,000 U (nM lysoGb3 x year). In the female
patients with a low lysoGb3 exposure of 0–1000 U (n=38), 36 were
asymptomatic or mildly affected. The two patients with a low lysoGb3
exposure who had a higher MSSI score suffered from hypertension and
obesity. These risk factors may have contributed to the higher MSSI
score. Of the female patients with a higher lysoGb3 exposure of 1000–
5000 (n=17), 11 were moderately affected (MSSI 20–39), but 6 had a
MSSI below 20. These 6 cases were examined in more detail. The ﬁrst
case (35 y, MSSI 10) had proteinuria, but no other complications. A
recent follow-up MRI examination, at the age of 40, revealed a lacunar
infarction. The second case (44 y, MSSI 9) had microalbuminuria,
modest LVH,whitematter lesions and hearing loss. The third case (15 y,
MSSI 10) had acroparesthesias and several white matter lesions. The
fourth case (49 y, MSSI 17) showed angiokeratoma, LVH, white matter
lesions, and microalbuminuria. The ﬁfth case (53 y, MSSI 18) had LVH,
white matter lesions and proteinuria. The sixth case (37 y, MSSI 6) had
LVH and angiokeratoma. In other words, 5 out of the 6 female patients
with relatively high lysoGb3 had signiﬁcant disease symptoms at the
time of the lysoGb3 assessment, not reﬂected in a high MSSI score
Table 2
Multiple regression analysis of contribution of plasma lysoGb3 to disease manifestations.
Linear regression Males Females
B-value per 100 nM lysoGb3 p B-value per 10 nM lysoGb3 p
MSSI 1.3±1.0 0.23 1.6±0.4 b0.001
LVmass −5.1±8.0 0.53 24.8±5.6⁎ b0.001
Renal function (mGFR) −7.1±6.8 0.32 0.3±1.6 0.84
Logistic regression Males Females
Odds ratio (95% CI) per 100 nM lysoGb3 p Odds ratio (95% CI) per 10 nM lysoGb3 p
MSSI (N20) 0.8 (0.2–2.4) 0.68 1.9 (1.1–3.5) 0.03
LVH 0.6 (0.2–2.0) 0.41 1.6 (0.9–2.7) 0.11
WML 6.1 (1.4–25.9) 0.015 1.2 (0.9–1.9) 0.18
Hearing loss 3.0 (0.9–10.1) 0.07 1.0 (0.4–2.4) 0.99
Renal failure (mGFR)** 1.5 (0.5–4.5) 0.49 1.3 (0.05–34.6) 0.87
Microalbuminuria 0.9 (0.5–1.8) 0.80 1.2 (0.9–1.6) 0.32
Proteinuria 0.9 (0.4–1.7) 0.66 1.0 (0.6–1.5) 0.93
Angiokeratoma 1.0 (0.6–1.9) 0.92 1.4 (1.0–1.9) 0.07
Acroparesthesia 2.3 (0.8–7.0) 0.14 1.0 (0.7–1.4) 0.94
B-value=19.5±5.5, p=0.001 when adjusted for hypertension.
Fig. 4. Correlation between plasma lysoGb3 concentration and incidence of white
matter lesions in male Fabry patients. Plasma lysoGb3 levels were correlated with
occurrence of white matter lesions in male Fabry patients (n=33).
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individual, had a low lysoGb3 exposure (802 U) together with a low
MSSI of 8. Table 3 shows that theproportionofmale patientswith severe
disease is clearly increasing with higher lysoGb3 exposure. Of the 12
male patients with a modestly higher lysoGb3 exposure of 1000–
5000 U, 8 were mildly affected. The remaining 4 patients were
moderately affected. Of the 12 patients with a lysoGb3 exposure of
5000–10,000, 6weremildly affected, 5moderately affected and a single
individual severely affected. The latter case was a smoker withTable 3
LysoGb3 exposure and disease severity.
LysoGb3 exposure b1000 U 1000-5
Females (n=55) Total n=38
Asymp-mild n=36
Moderate n=2#
Severe none
Total n
Mild n=
Modera
Severe
Males (n=37) Total n=1
Asymp-mild n=1
Moderate none
Severe none
Total n
Mild n=
Modera
Severe
LysoGb3 exposure=plasma lysoGb3 concentration x age; expressed in Units (nM x year).
Asymptomatic-mild=MSSI 0–19; moderate=MSSI 20–39; severe = MSSI N40.
* 5/6 patients with MSSI 0–19 had signiﬁcant symptoms; # hypertension, overweight; ##:hypertension, which may have contributed to his relatively high MSSI.
Finally, in the 12 male patients with a very high lysoGb3 exposure
exceeding 10,000 U, 6 were moderately affected and 5 were severely
affected. Only one individual was mildly affected with a MSSI of 17. The
percentage of moderately and severely affected patients increased
signiﬁcantly with increasing lysoGb3 exposure in both females
(pb0.001) and males (p=0.008). Finally, the relationship between
plasma lysoGb3 exposure and the incidence ofwhitematter lesionswas
examined more closely. It was found that in male Fabry patients the
plasma lysoGb3 exposure (Fig. 5B) correlates better than age (Fig. 5A)
withexistenceof awhitematter lesion. In female patients this difference
was less pronounced.
3.5. R112H and P60L mutation
A subset of patients did not classify for classical Fabry disease. This
concerned 11 patients with the R112H mutation (5 males, 7 females)
and 4 patients with the P60L mutation (2 males, 2 females). Their
lysoGb3 ranged from 0 to 11 nM in females and 0–20 nM in males.
Although, the α-Galactosidase A activity in plasma and leukocytes
was reduced in most of these individuals, they did not express any of
the classical Fabry symptoms. A single 61-year-old male from this
group developed renal insufﬁciency at the age of 43. A kidney biopsy
performed at that time led to the diagnosis of Fabry disease. Recent
reanalysis of that biopsy showed some storage in the epithelial cells,
but no storage in the endothelium as is usually detected in Fabry
patients (Fig. 6). This case was considered an atypical variant of Fabry
disease by the pathologist. Furthermore this patient suffered from
hypertension that could have attributed to development of renal000 U 5000–10,000 U N10,000 U
=17
6*
te n=11
none
None None
=12
8
te n=4
none
Total n=12
Mild n=6
Moderate n=5
Severe n=1##
Total n=12
Mild n=1
Moderate n=5
Severe n=6
hypertension, smoker.
Fig. 5.White matter lesions in females (A) and males (B) relation to lysoGb3 exposure
and to age. Plasma lysoGb3 exposure expressed in nM×year. WML: white matter lesion
detected by MRI.
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lysoGb3 values in males a diagnosis of Fabry disease may need
reconsideration in individuals with an α-Galactosidase A mutation
with unknown consequence.Fig. 6. (A) Kidney biopsy from the patient with the R112H mutation. Epithelial cells of the p
absent (original magniﬁcation 20,000×). (B) Kidney biopsy from a patient with a classical F
and endothelial cells (E) (original magniﬁcation 30,000×).4. Discussion
Our investigation of 92 hemizygotes and heterozygotes for Fabry
disease, seen at the Academic Medical Centre prior to therapy, has
revealed that measurement of plasma lysoGb3 concentration is useful
for conﬁrmation of the diagnosis of Fabry disease. In all hemizygous
male and adult heterozygous female Fabry patients the plasma
lysoGb3 concentration was found to be abnormally high and clearly
distinguishable from normal. In very young female Fabry hetero-
zygotes a lack of plasma lysoGb3 elevation may however be
uninformative. For example, we were unable to detect elevated
plasma lysoGb3 in a 7-year-old Fabry patient. However, at the age of
11 years the plasma lysoGb3 was clearly elevated. The ﬁndings for
plasma lysoGb3 levels sharply contrast with those for plasma Gb3
concentrations. Conﬁrmation of the diagnosis of Fabry disease by
demonstration of elevated plasma Gb3 concentration is only possible
in male Fabry patients. Most female Fabry patients show plasma Gb3
levels within the normal range.
Our study further revealed that plasma lysoGb3 is not elevated in a
number of individuals carrying an α-Galactosidase A gene with a
nucleotide change which is not unequivocally linked to Fabry disease.
Examples of this are the R112H substitution and the P60L substitution.
Although, the α-Galactosidase A activity in plasma and leukocytes is
reduced in these individuals, they do not develop marked elevated
plasma lysoGb3. Since their urinary Gb3 is not increased, it seems
questionable whether these individuals should be considered as Fabry
patients at all. These observations suggest that plasma lysoGb3
measurement may prove to be a useful additional assessment for
conﬁrmation of Fabry disease in individuals with an α-Galactosidase
A mutation with unknown consequence.
A pathophysiological role of elevated plasma lysoGb3 in Fabry
disease may be considered. Barbey and co-workers [22] were the ﬁrst
to report an increased carotid intima-media thickness in the absence
of atherosclerotic plaques in adult Fabry patients, a ﬁnding which was
soon conﬁrmed by others [21]. Barbey and colleagues [22] proposed
that a circulating factor contributes to the noted vessel remodelling in
Fabry patients and subsequent vasculopathy. We earlier demonstrated
that exposure of smooth cells in culture to lysoGb3 concentrations asodocytes show zebra bodies (arrow). In the endothelial cells (E) these zebra bodies are
abry mutation and phenotype. Zebrabodies (arrows) are present in both epithelial cells
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of these cells [20]. Our present investigation using multiple logistic and
linear regression with adjustments for age and cardiovascular risk
factors, revealed some signiﬁcant relationships between plasma
lysoGb3 concentration and clinical manifestations. This is remarkable
since relatively lownumbers ofmale (n=37)and female (n=55) Fabry
patients were studied. The relationships become more pronounced
when data of both genders are combined with appropriate adjustment
for gender. For example, the linear correlation between lysoGb3 and
MSSI is 1.4±0.5 (p=0.007) per 10 nM increase of lysoGb3 and 24.3±
5.3 g increase of LVmass (pb0.0001) per 10 nM increase of lysoGb3 for
the patients combined. The logistic correlation between lysoGb3 and
white matter lesions shows an odds ratio (95% CI) of 1.2 (1.0–1.3)
(p=0.004) for both males and females per 10 nM increase.
We investigated whether lifetime exposure to plasma lysoGb3
inﬂuences disease severity. The individual lifetime exposure was
crudely estimated by calculating the product of plasma lysoGb3 level
and age of the investigated subject. A correlation indeed was noted
between plasma lysoGb3 exposure and disease classiﬁcation, using
the Mainz severity scoring index (MSSI) [29], both for male and
female Fabry patients. This ﬁnding is striking since white matter
abnormalities and micro-albuminuria hardly contribute to the Mainz
severity score.
It should be mentioned that age by itself is a major factor that
determines the clinical outcome in Fabry patients. The contribution of
lysoGb3 on top of age is most apparent with respect to white matter
lesions: in patients with a high exposure to lysoGb3, white matter
lesions were clearly more frequently present. The inverse was true as
well: in the older male patients, only the ones with a relatively low
lysoGb3 level had not yet developedwhitematter lesions. For females,
the most important conclusion is that levels are much lower than in
males, but when relatively high lysoGb3 values are identiﬁed at a
young age, this almost invariably relates to the presence of disease
signs and/or symptoms.
Unfortunately, no IMT data had been collected prior to therapeutic
intervention for most of the Fabry patients included in this study. We
therefore are unable to correlate IMT values with plasma lysoGb3
concentration or estimated exposure. Very recently Barbey and collea-
gues reported a slight elevation in sphingosine-1-phosphate in plasma of
Fabry patients [33]. In their report it is suggested that this lipid
abnormality may underlie the carotid intima media thickening in Fabry
patients. Spingosine-1-phosphate is known to be an important regulator
of the vesselwall [34]. Since lysoGb3 and sphingosine-1-phosphate show
structural resemblance it is of interest to investigate the effect of lysoGb3
on sphingosine-1-phosphate signaling in the vessel wall.
It is surprising that our data suggest that plasma lysoGb3 concentra-
tion is an independent risk factor for different disease manifestations in
males and in females (white matter lesions in males and left ventricular
hypertrophy in females). Itwill beof interest to studya larger cohort of FD
patients with complete clinical assessment, particularly mildly affected
male patients, to establish whether the noted gender-difference truly
exists or is caused by the limited number of individuals investigated in
our study.
Since almost a decade enzyme replacement therapy, based on
chronic intravenous administration of recombinant α-Galactosidase
A, has become available for the treatment of Fabry patients [35–37].
Two enzyme preparations are currently registered. One enzyme is
produced by Chinese hamster ovary (CHO) cells with classic
recombinant technology (agalasidase β, Fabrazyme) and the other
enzyme is produced by cultured human skin ﬁbroblasts with an
activated promoter of the α-Gal A gene (agalasidase α, Replagal).
Both recombinant enzymes are quite comparable in properties and
differ only slightly in glycan composition [24]. We earlier reported on
responses in plasma Gb3 levels in Fabry patients treated with the two
enzyme preparations at several dosing regimens [37]. The impact of
enzyme replacement therapy on plasma lysoGb3 concentration issubject of a separate ongoing investigation. Preliminary ﬁndings were
reported in our previous study [20], indicating that treatment of Fabry
patients with either enzyme preparations gives rise to a reduction, but
not complete correction of plasma lysoGb3 [20]. Multiple regression
analyses revealed that, when adjusted for age and cardiovascular risk
factors, the plasma lysoGb3 concentration in male Fabry patients is an
independent risk for cerebral whitematter lesions and in female Fabry
patients for left ventricular hypertrophy. Our observation that
lysoGb3 concentration decreases upon enzyme replacement therapy
is therefore encouraging.
In conclusion, the measurement of plasma lysoGb3 is valuable
for conﬁrmation of the diagnosis of Fabry disease, particularly in
female heterozygotes. Our investigation indicates that exposure to
plasma lysoGb3 correlates with severity of disease manifestations.
Plasma lysoGb3 concentration is an independent risk factor for
development of cerebrovascular white matter lesions in male
patients and left ventricular mass in females. Further investigations
in patients and mice with an α-Galactosidase A deﬁciency will give
more insight into the role of circulating lysoGb3 in the vasculopathy
of Fabry disease.
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